Adaptate Biotherapeutics Raises $18 million in Series A2 Funding
Adaptate Biotherapeutics Raises $18 million in Series A2 Funding Investment will accelerate the progression of the Company’s lead therapeutic antibody programme towards the clinic and further expand its internal product pipeline Latest financing takes total [...]
Adaptate Biotherapeutics Appoints Stewart Kay as Chief Business Officer
Adaptate Biotherapeutics Appoints Stewart Kay as Chief Business Officer New CBO role to drive the Company’s Business and Corporate Development activities London, UK, 26 October 2020: Adaptate Biotherapeutics (Adaptate), a company focussed on developing [...]
Adaptate Biotherapeutics establishes Scientific Advisory Board with Professor Adrian Hayday as Chair
Adaptate Biotherapeutics establishes Scientific Advisory Board with Professor Adrian Hayday as Chair Professor Gillian Griffiths, Dr John Haurum, Dr Jessica Strid and Professor Sally Ward appointed to provide expert advice to progress company’s portfolio [...]
Adaptate Biotherapeutics appoints Dr Mihriban Tuna as Chief Scientific Officer
Adaptate Biotherapeutics appoints Dr Mihriban Tuna as Chief Scientific Officer London, UK, 11 March 2020: Adaptate Biotherapeutics (Adaptate), a company focussed on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced [...]
Adaptate Biotherapeutics named as one of 20 European biotech companies to follow in 2020
Adaptate Biotherapeutics named as one of 20 European biotech companies to follow in 2020 Adaptate Biotherapeutics was selected for Labiotech’s list of the 20 European biotech companies ‘that will be stealing the show in 2020’. [...]
Iontas & Adaptate Collaborate
IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets Cambridge, UK, 03 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has [...]
Adaptate Formed
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells GammaDelta Therapeutics spins-out new company to accelerate antibody-based assets towards clinical studies London, UK, 16th October 2019: GammaDelta Therapeutics, a company focussed on [...]